Phosphatidylserine for Cognitive Function

Verdict: Weak, formulation-dependent evidence for memory

Phosphatidylserine shows only weak, inconsistent support for cognitive function: the encouraging older trials used a bovine-brain form that is no longer sold, while modern soy-derived supplements perform less convincingly, with any benefit largely confined to people who start with poorer memory.

C 🟠 C Weak Evidence Published with Warning

🔬Why this grade7-layer evidence engine

The grade is weak (Tier C) because the most positive human data come from 1990s trials of bovine-cortex phosphatidylserine — Crook 1991 (PMID 2027477, n=149) and Cenacchi 1993 (PMID 8323999, n=494) — which reported memory and cognitive improvements in older adults but used a brain-derived form that was later discontinued over BSE/prion concerns. That evidence does not automatically transfer to the soy-derived product sold today.

Trials of the modern formulation are less convincing. A 2010 soybean-PS RCT (PMID 21103034, n=78) found no overall benefit, with improvement limited to a low-baseline-memory subgroup, and was industry-funded. A 2025 RCT in Chinese adults with mild cognitive impairment (PMID 39317299, n=190) did report gains on a few cognitive subscores, but effects were small and a 2022 meta-analysis judged the overall memory benefit too modest to be clinically meaningful.

Authorities reinforce the cautious read: the US FDA permits only a qualified health claim that carries a mandatory disclaimer calling the supporting science very limited and preliminary, and EFSA rejected the cognitive claim outright. Combined with heavy reliance on industry-funded subgroup findings, this supports a weak, published-with-warning verdict rather than a clear endorsement.

⚖️

Scoring transparency

All scores computed by a 7-layer evidence engine — fully auditable
Raw score 0.52
D
C
B
A
S
← counter-evidence / ineffectiveeffective / strong evidence →
Final grade
C · Published with Warning
Confidence
82%
Highly consistent evidence
Evidence level
E6
Multiple smaller RCTs (n<500)

How strongly each layer supports this effect

lower = less supportive
L1 ExamineGlobal benchmark
0.50
L3 MechanismPlausibility
0.50
L11 AI re-checkIndependent read
0.50
L5 Clinical bodiesAuthoritative stance
0.55
L2 PubMedPrimary literature
0.60
Against Mixed Supports
View the full decision path (audit trail)
  1. compute_raw_score — 加權公式: L2×0.30 + L3×0.25 + L5×0.25 + L11×0.10 + L1×0.10 = 0.515
  2. tier_from_score — 依分數區間映射至 tier letter
  3. apply_hec_rules — 無高階證據可裁決
  4. tier_strict_requirement_check — Tier 條件達標,未降階
  5. detect_disputes — 偵測到 0 個 hard + 1 個 soft dispute
  6. decide_status — 依 tier + dispute 結果決定 status

📄PubMed studies (4)L2 · primary research & systematic reviews

Effects of phosphatidylserine in age-associated memory impairment (Crook et al.)
PMID: 2027477 1991 RCT (double-blind) n = 149
Finding: BC-PS group improved vs placebo on learning/memory performance tests; effect concentrated in low-baseline-performance subgroup (p-values not in abstract).
View on PubMed
Cognitive decline in the elderly: double-blind placebo-controlled multicenter study on phosphatidylserine (Cenacchi et al.)
PMID: 8323999 1993 RCT (double-blind) n = 494
Finding: Statistically significant improvement vs placebo on behavioral and cognitive parameters in elderly with cognitive impairment; well tolerated.
View on PubMed
Soybean-Derived Phosphatidylserine Improves Memory Function of Elderly Japanese with Memory Complaints
PMID: 21103034 2010 RCT (double-blind) n = 78
Finding: No overall between-group difference (ceiling effects); only the low-baseline-memory subgroup showed significantly improved delayed verbal recall vs placebo (p<0.05).
🟠 Limited quality ⚠️ Industry-funded
View on PubMed
Food supplement containing phosphatidylserine on cognitive function in Chinese older adults with MCI: RCT
PMID: 39317299 2025 RCT (double-blind) n = 190
Finding: Significant gains in 3 cognitive sub-scores: arithmetic (beta 0.688, 95% CI 0.103-1.274), similarity (beta 1.070, 95% CI 0.472-1.667), short-term memory (beta 0.600, 95% CI 0.399-0.800).
Effect size: beta 0.60-1.07 on sub-scale scores
View on PubMed

🏛️Regulatory & authoritative positionsL4/L5 · FDA / EMA / NIH ODS / Cochrane / Mayo …

L4d TW TFDA / 衛福部
Neutral
訂定「食品原料磷脂醯絲胺酸(Phosphatidylserine)之使用限制」,並自中華民國一百十四年七月一日生效。 source↗
PMID 100% verifiedevery citation checked via NCBI Entrez
🔬4 PubMed studiesindependently re-checked by multiple sub-agents
engine_version: v1.0 claim_id: CLM-COND-cognitive-function-INT-phosphatidylserine-001 繁體中文版 →